HPN 328 targets DLL-3 and is tested against small-cell lung cancer (NCT04471727), HPN217 targets BCMA and is tested in r/r MM (NCT04184050), HPN424 targets PSMA and is tested in advanced prostate cancer (NCT03577028), while HPN536 targets mesothelin (MSLN) and is tested in various advanced solid tumors, including ovarian or pancreatic cancer, and malignant pleural mesothelioma (MPM, NCT03872206). This evidence concerns the gene FOLH1 and prostate cancer.